| HOME >> BIOLOGY >> TECHNOLOGY |
PHOENIX, Jan. 6, 2012 /PRNewswire/ -- VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT™ system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells. Development of the fully automated system was funded in part by a $2.6 million grant from the National Institutes of Health's (NIH) BRDG-SPAN program (Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies). Separately, VisionGate announced that it will be presenting at the OneMedForum 2012 Finance Conference in San Francisco on Tuesday, January 10, 2012.
VisionGate's first diagnostic application for the automated Cell-CT system is the LuCED® test, a non-invasive test in development for lung cancer screening. LuCED will initially be marketed in conjunction with x-ray computed tomography (CT) scans to detect lung cancer in high-risk individuals at its earliest stages, when curative therapy is still feasible.
"Achieving full automation of the Cell-CT system is a major milestone for VisionGate," said Alan Nelson, PhD, Chairman and CEO of VisionGate. "To realize the exceptional potential of this breakthrough 3D imaging technology for disease diagnosis and prognosis in large patient populations, it had to be developed as part of a fully automated system that can process patient samples rapidly and efficiently. We believe the automated Cell-CT platform could revolutionize cell-based diagnostics, both by enabling early disease detection and by providing pathologists with a powerful new tool for a wide range of applications. We are grateful for the support from the NIH that helped us reach this critical goal."
Dr. Nelson continued, "In the near-term, automation of the Cell-CT platform sets the stage for submis
'/>"/>
| SOURCE VisionGate, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
2. Vermillion Sharpens Focus and Streamlines Operations in 2012
3. Bionovo Announces $5 Million Financing
4. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
5. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
6. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
7. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
8. CeNeRx BioPharma Completes $4.85 Million Financing
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. InnoPharma Completes $15 Million Series A Financing
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |